Engineering immune cells to fight leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study uses blood samples from people with acute myeloid leukemia (AML) and from healthy stem cell donors to learn how to make immune cells better at killing cancer. The goal is to develop a new type of treatment that helps the body's own defenses fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with acute myeloid leukemia (AML), or you are a healthy stem cell donor whose blood is stored in the hospital's biobank.
- You have a specific genetic marker (HLA type) that the study needs.
- You can give written permission to use your blood sample for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.